Table 2:
Global years lived with disability (YLDs) for a comprehensive set of 289 causes and select sequelae in 1990 and 2010, for all ages, both sexes combined, and per 100 000
| All ages YLDs (thousands) |
YLDs (per 100 000) |
|||||
|---|---|---|---|---|---|---|
| 1990 | 2010 | %Δ | 1990 | 2010 | %Δ | |
| All causes | 583 393 (484 649-694 406) | 777 401 (648 158-921 711) | 333% | 11 004 (9142-13 098) | 11 283 (9407-13 378) | 2.5% |
| Communicable, maternal, neonatal, and nutritional disorders | 113 925 (85 875-148 463) | 119 164 (91 399-152 096) | 46% | 2149 (1620-2800) | 1730 (1327-2207) | −19.5% |
| HIV/AIDS and tuberculosis | 7681 (5222-10 722) | 11 117 (7718-15 187) | 44.7% | 145 (99-202) | 161 (112-220) | 11.4% |
| Tuberculosis | 6085 (4020-8737) | 6774 (4500-9756) | 11.3% | 115 (76-165) | 98 (65-142) | −14.3% |
| HIV/AIDS | 1596 (1132-2125) | 4342 (3142-5629) | 172.2% | 30 (21-40) | 63(46-82) | 109.4% |
| HIV disease resulting in mycobacterial infection | 220 (143-314) | 1224 (793-1746) | 456.8% | 4(3-6) | 18 (12-25) | 328.4% |
| HIV disease resulting in other specified or unspecified diseases | 1376 (967-1857) | 3119 (2241-4107) | 126.7% | 26 (18-35) | 45 (33-60) | 74.4% |
| HIV pre-AIDS asymptomatic | 376 (227-569) | 889 (546-1338) | 136.8% | 7 (4-11) | 13(8-19) | 82.2% |
| HIV pre-AIDS symptomatic | 289 (193-411) | 531 (350-756) | 83.6% | 5 (4-8) | 8 (5-11) | 41.3% |
| AIDS with antiretroviral treatment | 0 (0-0) | 389 (251-578) | .. | 0 (0-0) | 6 (4-8) | .. |
| AIDS without antiretroviral treatment | 711 (483-958) | 1309 (913-1758) | 84.2% | 13 (9-18) | 19 (13-26) | 41.7% |
| Diarrhoea, lower respiratory infections, meningitis, and other common infectious diseases | 18 579 (13 419-25 301) | 19 921 (14 241-27 439) | 7.2% | 350 (253-477) | 289 (207-398) | −17.5% |
| Diarrhoeal diseases | 7654 (5135-10 855) | 8045 (5371-11 366) | 5.1% | 144 (97-205) | 117 (78-165) | −19.1% |
| Cholera | 115 (59-188) | 80 (42-134) | −30.1% | 2 (1-4) | 1 (1-2) | −46.2% |
| Other salmonella infections | 263 (150-410) | 341 (202-523) | 29.8% | 5(3-8) | 5(3-8) | −0.1% |
| Shigellosis | 703 (391-1111) | 744 (440-1147) | 5.8% | 13 (7-21) | 11 (6-17) | −18.6% |
| Enteropathogenic E coli infection | 972 (438-1652) | 845 (387-1416) | −13.0% | 18 (8-31) | 12 (6-21) | −33.1% |
| Enterotoxigenic E coli infection | 889 (520-1409) | 1065 (649-1643) | 19.8% | 17 (10-27) | 15 (9-24) | −7.8% |
| Campylobacter enteritis | 753 (407-1211) | 746 (416-1180) | −1.0% | 14 (8-23) | 11 (6-17) | −23.8% |
| Campylobacter enteritis | 753 (406-1211) | 746 (415-1181) | −0.9% | 14 (8-23) | 11 (6-17) | −23.8% |
| Guillain-Barre syndrome due to C enteritis | 1 (0-1) | 1 (1-2) | 35.7% | <0.5 (0-0.5) | <0.5 (0-0.5) | 4.4% |
| Amoebiasis | 142 (84-217) | 205 (126-314) | 44.1% | 3 (2-4) | 3(2-5) | 10.9% |
| Cryptosporidiosis | 651 (312-1101) | 661 (316-1096) | 1.6% | 12 (6-21) | 10 (5-16) | −21.8% |
| Rotaviral enteritis | 1159 (624-1885) | 1269 (701-2006) | 9.5% | 22 (12-36) | 18 (10-29) | −15.8% |
| Other diarrhoeal diseases | 2007 (1027-3412) | 2089 (1054-3521) | 4.1% | 38 (19-64) | 30 (15-51) | −19.9% |
| Typhoid and paratyphoid fevers | 134 (25-348) | 172 (33-435) | 27.8% | 3 (0-7) | 2(0-6) | −1.7% |
| Typhoid and paratyphoid fevers | 124 (16-337) | 159 (20-423) | 27.8% | 2(0-6) | 2(0-6) | −1.6% |
| Liver abscess and cysts due to typhoid and paratyphoid fevers | 10 (7-15) | 13 (8-20) | 27.4% | <0.5 (0-0.5) | <0.5 (0-0.5) | −1.9% |
| Lower respiratory infections | 2113 (1444-2941) | 2331 (1592-3240) | 10.3% | 40 (27-55) | 34 (23-47) | −15.1% |
| Influenza | 510 (344-714) | 583 (393-815) | 14.2% | 10 (6-13) | 8(6-12) | −12.1% |
| Influenza | 510 (343-713) | 582 (392-814) | 14.2% | 10 (6-13) | 8(6-12) | −12.1% |
| Guillain-Barre syndrome due to influenza | 1 (1-2) | 2(1-3) | 34.3% | <0.5 (0-0.5) | <0.5 (0-0.5) | 3.3% |
| Pneumococcal pneumonia | 298 (203-414) | 367 (248-509) | 23.2% | 6 (4-8) | 5 (4-7) | −5.2% |
| H influenzae type B pneumonia | 216 (145-306) | 201 (134-286) | −6.6% | 4(3-6) | 3 (2-4) | −28.2% |
| Respiratory syncytial virus pneumonia | 52 (31-82) | 36 (21-55) | −31.3% | 1 (1-2) | 1 (0-1) | −47.2% |
| Other lower respiratory infections | 1037 (702-1459) | 1144 (779-1589) | 10.2% | 20 (13-28) | 17 (11-23) | −15.2% |
| Upper respiratory infections | 1438 (755-2542) | 1728 (911-3050) | 20.2% | 27 (14-48) | 25 (13-44) | −7.5% |
| Upper respiratory infections | 1437 (753-2541) | 1727 (910-3048) | 20.2% | 27 (14-48) | 25 (13-44) | −7.5% |
| Guillain-Barre syndrome due to upper respiratory infections | 1 (1-2) | 2(1-3) | 33.8% | <0.5 (0-0.5) | <0.5 (0-0.5) | 3.0% |
| Otitis media | 3794 (2456-5829) | 4436 (2887-6668) | 16.9% | 72 (46-110) | 64 (42-97) | −10.0% |
| Otitis media | 1359 (819-2150) | 1613 (979-2594) | 18.7% | 26 (15-41) | 23 (14-38) | −8.7% |
| Hearing loss due to otitis media | 2435 (1423-3929) | 2824 (1669-4533) | 16.0% | 46 (27-74) | 41 (24-66) | −10.8% |
| Meningitis | 2757 (1973-3732) | 2628 (1857-3643) | −4.7% | 52 (37-70) | 38 (27-53) | −26.7% |
| Pneumococcal meningitis | 920 (624-1298) | 886 (595-1254) | −3.7% | 17 (12-24) | 13(9-18) | −25.9% |
| Spneumoniae meningitis | 9 (5-14) | 11 (6-17) | 19.6% | <0.5 (0-0.5) | <0.5 (0-0.5) | −8.0% |
| Long term sequelae due to S pneumoniae meningitis | 571 (324-899) | 488 (261-806) | −14.5% | 11 (6-17) | 7 (4-12) | −34.2% |
| Seizures due to S pneumoniae meningitis | 80 (52-118) | 79 (55-113) | −0.4% | 2(1-2) | 1 (1-2) | −23.4% |
| Hearing loss due to Spneumoniae meningitis | 261 (154-420) | 308 (185-500) | 18.2% | 5 (3-8) | 4 (3-7) | −9.0% |
| H influenzae type B meningitis | 646 (429-933) | 371 (247-524) | −42.6% | 12 (8-18) | 5 (4-8) | −55.8% |
| H influenzae type B meningitis | 10 (6-17) | 7 (4-12) | −32.0% | <0.5 (0-0.5) | <0.5 (0-0.5) | −47.7% |
| Long term sequelae due to H influenzae type B meningitis | 448 (253-715) | 233 (124-368) | −48.4% | 8(5-13) | 3(2-5) | −60.0% |
| Seizures due to H influenzae type B meningitis | 65 (38-110) | 31 (18-51) | −52.2% | 1(1-2) | <0.5 (0-1) | −63.3% |
| Hearing loss due to H influenzae type B meningitis | 123 (74-198) | 100 (60-160) | −18.5% | 2 (1-4) | 1 (1-2) | −37.3% |
| Meningococcal infection | 424 (302-597) | 403 (281-566) | −4.8% | 8 (6-11) | 6 (4-8) | −26.7% |
| Meningococcal infection | 6 (4-10) | 7 (4-12) | 13.0% | <0.5 (0-0.5) | <0.5 (0-0.5) | −13.0% |
| Long term sequelae due to meningococcal infection | 195 (115-306) | 165 (92-269) | −15.2% | 4(2-6) | 2 (1-4) | −34.8% |
| Seizures due to meningococcal infection | 35 (23-52) | 28 (18-40) | −21.4% | 1 (0-1) | <0.5 (0-1) | −39.5% |
| Hearing loss due to meningococcal infection | 187 (110-297) | 203 (119-325) | 8.6% | 4 (2-6) | 3(2-5) | −16.5% |
| Other meningitis | 733 (509-1036) | 930 (647-1361) | 27.0% | 14 (10-20) | 14 (9-20) | −2.3% |
| Other meningitis | 37 (24-53) | 49 (31-72) | 34.4% | 1 (0-1) | 1 (0-1) | 3.4% |
| Long term sequelae due to other bacterial meningitis infection | 283 (157-446) | 289 (149-476) | 2.2% | 5 (3-8) | 4 (2-7) | −21.4% |
| Seizures due to other bacterial meningitis infection | 48 (32-71) | 46 (31-66) | −4.0% | 1 (1-1) | 1 (0-1) | −26.1% |
| Hearing loss due to other bacterial meningitis infection | 365 (221-572) | 546 (322-883) | 49.6% | 7 (4-11) | 8 (5-13) | 15.1% |
| Encephalitis | 183 (120-260) | 205 (133-292) | 12.6% | 3 (2-5) | 3 (2-4) | −13.4% |
| Encephalitis | 5 (3-9) | 7 (4-12) | 35.7% | <0.5 (0-0.5) | <0.5 (0-0.5) | 4.4% |
| Motor cognitive impairments due to encephalitis | 177 (117-253) | 198 (128-283) | 11.9% | 3(2-5) | 3 (2-4) | −13.9% |
| Diphtheria | <0'5 (0-2) | <0.5 (0-1) | −49.1% | <0.5 (0-0.5) | <0.5 (0-0.5) | −60.9% |
| Whooping cough | 181 (103-287) | 122 (70-195) | −32.5% | 3(2-5) | 2(1-3) | −48.0% |
| Tetanus | 78 (35-159) | 21(9-43) | −72.3% | 1 (1-3) | <0.5 (0-1) | −78.7% |
| Tetanus | 77 (35-158) | 21(9-43) | −72.3% | 1 (1-3) | <0.5 (0-1) | −78.7% |
| Long-term sequelae from neonatal tetanus | 1 (0-2) | <0.5 (0-1) | −73.2% | <0.5 (0-0.5) | <0.5 (0-0.5) | −79.4% |
| Measles | 106 (58-180) | 31 (17-51) | −70.8% | 2(1-3) | <0.5 (0-1) | −77.5% |
| Varicella | 142 (87-219) | 202 (124-308) | 42.0% | 3 (2-4) | 3 (2-4) | 9.3% |
| Chickenpox | 7 (2-16) | 7 (2-16) | −0.9% | <0.5 (0-0.5) | <0.5 (0-0.5) | −23.8% |
| Herpes zoster | 135 (84-209) | 195 (120-295) | 44.3% | 3 (2-4) | 3 (2-4) | 11.0% |
| Neglected tropical diseases and malaria | 23 491 (15 715-36 639) | 22 219 (15 693-31 544) | −5.4% | 443 (296-691) | 322 (228-458) | −27.2% |
| Malaria | 2662 (1257-4481) | 4070 (1853-6980) | 52.9% | 50 (24-85) | 59 (27-101) | 17.7% |
| Malaria | 433 (194-854) | 498 (218-933) | 14.8% | 8(4-16) | 7 (3-14) | −11.6% |
| Anaemia due to malaria | 2127 (833-3972) | 3367 (1312-6294) | 58.3% | 40 (16-75) | 49 (19-91) | 21.8% |
| Motor cognitive impairments due to malaria | 104 (41-273) | 211(81-556) | 102.8% | 2(1-5) | 3 (1-8) | 56.0% |
| Chagas disease | 324 (108-594) | 303(106-573) | −6.4% | 6(2-11) | 4(2-8) | −28.0% |
| Acute Chagas disease | 31 (7-62) | 28 (7-59) | −8.8% | 1(0-1) | <0.5 (0-1) | −29.8% |
| Chronic heart disease due to Chagas disease | 213 (38-429) | 195 (36-411) | −8.4% | 4(1-8) | 3 (1-6) | −29.5% |
| Chronic digestive disease due to Chagas disease | 73 (8-178) | 67 (7-157) | −8.5% | 1(0-3) | 1 (0-2) | −29.6% |
| Heart failure due to Chagas disease | 7 (4-10) | 13 (8-19) | 92.6% | <0.5 (0-0.5) | <0.5 (0-0.5) | 48.2% |
| Leishmaniasis | 113 (53-215) | 124 (60-235) | 10.2% | 2 (1-4) | 2(1-3) | −15.2% |
| Visceral leishmaniasis | 8 (2-16) | 6(2-13) | −17.2% | <0.5 (0-0.5) | <0.5 (0-0.5) | −36.3% |
| Cutaneous leishmaniasis | 105 (47-206) | 118 (56-229) | 12.2% | 2 (1-4) | 2(1-3) | −13.7% |
| African trypanosomiasis | 33 (12-86) | 8(2-25) | −75.2% | 1(0-2) | <0.5 (0-0.5) | −80.9% |
| Schistosomiasis | 1797 (923-3413) | 2986 (1541-5666) | 66.2% | 34 (17-64) | 43 (22-82) | 27.9% |
| Schistosomiasis | 696 (229-1579) | 1148 (377-2607) | 65.0% | 13 (4-30) | 17 (5-38) | 27.0% |
| Mild diarrhoea due to schistosomiasis | 1 (0-1) | 1 (1-2) | 77.2% | <0.5 (0-0.5) | <0.5 (0-0.5) | 36.3% |
| Anaemia due to schistosomiasis | 433 (219-766) | 687 (344-1217) | 58.8% | 8 (4-14) | 10 (5-18) | 22.2% |
| Hepatomegaly due to schistosomiasis | 104 (47-200) | 185(84-355) | 77.8% | 2 (1-4) | 3(1-5) | 36.8% |
| Haematemesis due to schistosomiasis | 39 (26-55) | 69 (46-97) | 76.6% | 1(0-1) | 1 (1-1) | 35.9% |
| Ascites due to schistosomiasis | 31 (21-44) | 56 (38-77) | 78.9% | 1 (0-1) | 1(1-1) | 37.7% |
| Dysuria due to schistosomiasis | 174 (80-334) | 298 (135-572) | 71.0% | 3(2-6) | 4(2-8) | 31.5% |
| Bladder pathology due to schistosomiasis | 159 (72-304) | 268 (122-515) | 68.9% | 3 (1-6) | 4 (2-7) | 30.0% |
| Hydronephrosis due to schistosomiasis | 162 (74-310) | 277(126-533) | 71.5% | 3 (1-6) | 4(2-8) | 32.0% |
| Cysticercosis | 484 (378-600) | 457 (357-566) | −5.5% | 9(7-11) | 7 (5-8) | −27.3% |
| Echinococcosis | 89 (44-187) | 110 (55-228) | 23.9% | 2 (1-4) | 2 (1-3) | −4.7% |
| Chronic respiratory disease due to echinococcosis | 2 (1-6) | 3 (1-7) | 22.8% | <0.5 (0-0.5) | <0.5 (0-0.5) | −5.5% |
| Epilepsy due to echinococcosis | 13 (6-28) | 16 (8-32) | 24.1% | <0.5 (0-1) | <0.5 (0-0.5) | −4.5% |
| Abdominopelvic problems due to echinococcosis | 73 (36-155) | 91 (43-193) | 23.9% | 1 (1-3) | 1 (1-3) | −4.7% |
| Lymphatic filariasis | 2368 (1551-3399) | 2775 (1807-4000) | 17.2% | 45 (29-64) | 40 (26-58) | −9.9% |
| Lymphoedema | 955 (585-1454) | 1151 (698-1773) | 20.5% | 18 (11-27) | 17 (10-26) | −7.3% |
| Hydrocele due to lymphatic filariasis | 1414 (842-2103) | 1624 (981-2450) | 14.9% | 27 (16-40) | 24 (14-36) | −11.6% |
| Onchocerciasis | 512 (361-687) | 494 (360-656) | −3.5% | 10 (7-13) | 7 (5-10) | −25.7% |
| Skin disease due to onchocerciasis | 407 (277-559) | 352 (240-486) | −13.3% | 8(5-11) | 5 (3-7) | −33.3% |
| Vision loss due to onchocerciasis | 105 (79-134) | 142 (108-185) | 34.5% | 2(1-3) | 2 (2-3) | 3.5% |
| Trachoma | 144 (104-189) | 334 (243-438) | 132.5% | 3 (2-4) | 5 (4-6) | 78.9% |
| Dengue | 6(2-13) | 12 (6-23) | 103.9% | <0.5 (0-0.5) | <0.5 (0-0.5) | 56.9% |
| Dengue | 5(2-11) | 10 (5-20) | 105.9% | <0.5 (0-0.5) | <0.5 (0-0.5) | 58.5% |
| Post-dengue chronic fatigue syndrome | 1 (0-2) | 2 (0-4) | 92.6% | <0.5 (0-0.5) | <0.5 (0-0.5) | 48.2% |
| Yellow fever | <0.5 (0-0.5) | <0.5 (0-0.5) | 15.1% | <0.5 (0-0.5) | <0.5 (0-0.5) | −11-4% |
| Rabies | <0.5 (0-1) | <0.5 (0-1) | −56.7% | <0.5 (0-0.5) | <0.5 (0-0.5) | −66.7% |
| Intestinal nematode infections | 8741 (4778-15 094) | 4980 (2722-8442) | −43-0% | 165 (90-285) | 72 (40-123) | −56.2% |
| Ascariasis | 3950(2080-6805) | 1111 (618-1864) | −71'9% | 75 (39-128) | 16 (9-27) | −78.4% |
| Ascariasis infestation | 1995 (1091-3254) | 758 (419-1232) | −62.0% | 38 (21-61) | 11 (6-18) | −70.8% |
| Severe wasting due to ascariasis | 49 (32-72) | 43 (28-62) | −12.8% | 1 (1-1) | 1(0-1) | −32.9% |
| Mild abdominopelvic problems due to ascariasis | 1906 (871-3673) | 310 (139-598) | −83.7% | 36 (16-69) | 4(2-9) | −87.5% |
| Trichuriasis | 857 (465-1420) | 638 (349-1061) | −25.5% | 16 (9-27) | 9 (5-15) | −42.7% |
| Trichuriasis infestation | 677 (367-1104) | 504 (277-821) | −25.6% | 13 (7-21) | 7 (4-12) | −42.8% |
| Severe wasting due to trichuriasis | 9(5-13) | 9(5-13) | −0.5% | <0.5 (0-0.5) | <0.5 (0-0.5) | −23.4% |
| Mild abdominopelvic problems due to trichuriasis | 171 (77-327) | 126 (57-246) | −26.3% | 3 (1-6) | 2 (1-4) | −43.3% |
| Hookworm disease | 3934(2056-6983) | 3231(1695-5732) | −17.9% | 74 (39-132) | 47 (25-83) | −36.8% |
| Hookworm infestation | 1315 (718-2150) | 1011 (556-1655) | −23.1% | 25 (14-41) | 15(8-24) | −40.9% |
| Severe wasting due to hookworm disease | 34 (21-49) | 42 (27-61) | 23.4% | 1 (0-1) | 1(0-1) | −5.0% |
| Mild abdominopelvic problems due to hookworm disease | 241(110-462) | 217(98-422) | −10.0% | 5(2-9) | 3(1-6) | −30.8% |
| Anaemia due to hookworm disease | 2344 (983-4348) | 1962 (895-3672) | −16.3% | 44 (19-82) | 28 (13-53) | −35.6% |
| Food-borne trematodiases | 2394 (635-8501) | 1875 (708-4837) | −21.7% | 45 (12-160) | 27 (10-70) | −39.7% |
| Heavy clonorchiasis | 367 (95-1145) | 296 (100-822) | −19.4% | 7 (2-22) | 4(1-12) | −37.9% |
| Heavy fascioliasis | 32 (18-53) | 42 (26-65) | 32.5% | 1 (0-1) | 1(0-1) | 2.0%% |
| Heavy intestinal fluke infection | 101 (58-179) | 106 (64-170) | 4.9% | 2(1-3) | 2(1-2) | −19.3% |
| Heavy opisthorchiasis | 48 (29-77) | 60 (37-92) | 27.0% | 1 (1-1) | 1(1-1) | −2.3% |
| Cerebral paragonimiasis | 57 (7-245) | 43 (8-148) | −25.2% | 1 (0-5) | 1 (0-2) | −42.4% |
| Heavy paragonimiasis | 1789 (233-7696) | 1328 (280-4234) | −25.8% | 34 (4-145) | 19 (4-61) | −42.9% |
| Other neglected tropical diseases | 3825 (2517-6057) | 3690 (2556-5303) | −3.5% | 72 (47-114) | 54 (37-77) | −25.8% |
| Other neglected tropical disease | 1007 (533-2568) | 949 (657-1557) | −5.8% | 19 (10-48) | 14 (10-23) | −27.5% |
| Anaemia due to other neglected tropical diseases | 2873 (1920-4163) | 2800 (1857-4054) | −2.5% | 54 (36-79) | 41 (27-59) | −25.0% |
| Maternal disorders | 1394 (935-2271) | 1790 (1138-2936) | 28.4% | 26 (18-43) | 26 (17-43) | −1.2% |
| Maternal haemorrhage | 143 (84-234) | 98 (61-151) | −31.7% | 3 (2-4) | 1 (1-2) | −47.5% |
| Maternal haemorrhage | 29 (18-46) | 19 (12-29) | −34.2% | 1 (0-1) | <0.5 (0-0.5) | −49.4% |
| Anaemia due to maternal haemorrhage | 114(65-193) | 79 (47-124) | −31.1% | 2 (1-4) | 1 (1-2) | −47.0% |
| Maternal sepsis | 80 (46-128) | 42 (25-65) | −48.4% | 2(1-2) | 1 (0-1) | −60.3% |
| Hypertensive disorders of pregnancy | 69 (41-111) | 93 (53-151) | 33.2% | 1(1-2) | 1 (1-2) | 2.5% |
| Pre-eclampsia | 60 (33-100) | 83 (44-141) | 38.9% | 1(1-2) | 1 (1-2) | 6.9% |
| Eclampsia | 4 (1-7) | 3 (1-7) | −14.6% | <0.5 (0-0.5) | <0.5 (0-0.5) | −34.3% |
| Long-term sequelae for hypertensive disorders of pregnancy | 6(1-15) | 7 (2-15) | 6.3% | <0.5 (0-0.5) | <0.5 (0-0.5) | −18.2% |
| Obstructed labour | 809 (458-1493) | 1182 (641-2194) | 46.0% | 15(9-28) | 17 (9-32) | 12.4% |
| Obstructed labour | 77 (40-140) | 34 (19-57) | −56.1% | 1(1-3) | <0.5 (0-1) | −66.3% |
| Fistula | 732 (390-1425) | 1148 (601-2138) | 56.8% | 14 (7-27) | 17 (9-31) | 20.6% |
| Abortion | 27 (15-52) | 32 (19-59) | 19.8% | 1 (0-1) | <0.5 (0-1) | −7.8% |
| Other maternal disorders | 264 (180-420) | 343 (225-526) | 30.1% | 5(3-8) | 5(3-8) | 0.1% |
| Neonatal disorders | 8422(6368-10706) | 9464 (7167-11 937) | 12.4% | 159 (120-202) | 137 (104-173) | −13.5% |
| Preterm birth complications | 2298 (1743-2895) | 2982 (2236-3716) | 29.7% | 43 (33-55) | 43 (32-54) | −0.2% |
| Impairment due to preterm birth complications | 2041 (1471-2613) | 2636 (1882-3359) | 29.1% | 39 (28-49) | 38 (27-49) | −0.7% |
| Retinopathy of prematurity due to preterm birth complications | 257 (154-376) | 347 (212-508) | 34.9% | 5 (3-7) | 5 (3-7) | 3.8% |
| Neonatal encephalopathy (birth asphyxia/trauma) | 5625 (4116-7298) | 6132 (4471-8030) | 9.0% | 106 (78-138) | 89 (65-117) | −16.1% |
| Sepsis and other infectious disorders of the newborn baby | 18 (9-32) | 23 (12-40) | 24.9% | <0.5 (0-1) | <0.5(0-1) | −3.9% |
| Other neonatal disorders | 481 (357-618) | 328 (244-417) | −31.8% | 9(7-12) | 5 (4-6) | −47.5% |
| Nutritional deficiencies | 49 887 (34 714-70 780) | 49 942 (34 705-70 350) | 0.1% | 941(655-1335) | 725 (504-1021) | −23.0% |
| Protein-energy malnutrition | 3200 (2071-4743) | 2720(1766-3972) | −15.0% | 60 (39-89) | 39 (26-58) | −34.6% |
| Kwashiokor or marasmus due to protein-energy malnutrition | 298 (155-520) | 197 (103-339) | −33.7% | 6 (3-10) | 3(1-5) | −49.0% |
| Severe wasting due to protein-energy malnutrition | 2906 (1803-4418) | 2530 (1604-3772) | −12.9% | 55 (34-83) | 37 (23-55) | −33.0% |
| Iodine deficiency | 3181 (2049-4912) | 3889(2468-6136) | 22.3% | 60 (39-93) | 56 (36-89) | −5.9% |
| Goitre due to iodine deficiency | 2902 (1823-4617) | 3767 (2382-5990) | 29.8% | 55 (34-87) | 55 (35-87) | −0.1% |
| Idiopathic intellectual disability due to iodine deficiency | 271 (181-386) | 113 (73-167) | −58.4% | 5 (3-7) | 2(1-2) | −68.0% |
| Heart failure due to iodine deficiency | 7(5-11) | 10 (6-14) | 33.3% | <0.5 (0-0.5) | <0.5 (0-0.5) | 2.6% |
| Vitamin A deficiency | 740 (565-941) | 806 (612-1037) | 9.0% | 14 (11-18) | 12 (9-15) | −16.1% |
| Iron-deficiency anaemia | 42 731 (28 506-61 896) | 42 494 (28 170-61 626) | −0.6% | 806 (538-1167) | 617 (409-894) | −23.5% |
| Iron-deficiency anaemia | 42 728 (28 497-61 897) | 42 505 (28 166-61 656) | −0.5% | 806 (538-1168) | 617(409-895) | −23.5% |
| Heart failure due to iron-deficiency anaemia | 17 (11-24) | 24 (16-36) | 46.7% | <0.5 (0-0.5) | <0.5(0-1) | 12.9% |
| Other nutritional deficiencies | 35 (31-44) | 32 (24-36) | −9.2% | 1 (1-1) | <0.5(0-1) | −30.1% |
| Other communicable, maternal, neonatal, and nutritional disorders | 4472 (3188-6195) | 4711(3352-6562) | 5.3% | 84 (60-117) | 68 (49-95) | −18.9% |
| Sexually transmitted diseases excluding HIV | 1111 (589-2072) | 1298 (704-2439) | 16.9% | 21 (11-39) | 19 (10-35) | −10.0% |
| Syphilis | 73 (3-156) | 91 (4-200) | 25.5% | 1(0-3) | 1 (0-3) | −3.4% |
| Sexually transmitted chlamydial diseases | 560 (268-1025) | 669 (324-1233) | 19.6% | 11 (5-19) | 10 (5-18) | −8.0% |
| Sexually transmitted chlamydial diseases | 507 (233-952) | 609 (281-1143) | 20.1% | 10 (4-18) | 9 (4-17) | −7.6% |
| Salpingitis, inflammatory disease of cervix, and other female pelvic inflammatory diseases due to sexually transmitted chlamydial diseases | 27 (16-43) | 25 (15-40) | −7.5% | 1(0-1) | <0.5(0-1) | −28.8% |
| Infertility due to sexually transmitted chlamydial diseases | 25 (9-53) | 35 (14-72) | 37.7% | <0.5 (0-1) | 1 (0-1) | 6.0% |
| Gonococcal infection | 184 (94-336) | 249 (123-450) | 35.1% | 3(2-6) | 4 (2-7) | 4.0% |
| Gonococcal infection | 147 (69-282) | 207(96-390) | 40.7% | 3(1-5) | 3 (1-6) | 8.3% |
| Salpingitis, inflammatory disease of cervix, and other female pelvic inflammatory diseases due to gonococcal infection | 20 (12-33) | 19 (11-31) | −7.7% | <0.5 (0-1) | <0.5 (0-0.5) | −29.0% |
| Infertility due to gonococcal infection | 17(7-35) | 23 (9-47) | 37.7% | <0.5 (0-1) | <0.5(0-1) | 5.9% |
| Trichomoniasis | 182 (0-549) | 167 (0-493) | −8.4% | 3 (0-10) | 2 (0-7) | −29.5% |
| Other sexually transmitted diseases | 112 (68-181) | 122 (74-200) | 9.3% | 2 (1-3) | 2 (1-3) | −15.9% |
| Other sexually transmitted diseases | 70 (42-111) | 64 (39-105) | −7.8% | 1 (1-2) | 1(1-2) | −29.0% |
| Infertility due to other sexually transmitted diseases | 42 (17-91) | 58 (23-125) | 37.7% | 1 (0-2) | 1 (0-2) | 5.9% |
| Hepatitis | 449 (230-810) | 542 (280-981) | 20.7% | 8 (4-15) | 8 (4-14) | −7.1% |
| Acute hepatitis A | 172 (85-294) | 185 (95-311) | 7.6% | 3(2-6) | 3(1-5) | −17.2% |
| Acute hepatitis B | 194 (24-456) | 248 (28-585) | 28.1% | 4(0-9) | 4(0-8) | −1.4% |
| Acute hepatitis C | 24 (4-50) | 39 (7-79) | 61.2% | <0.5 (0-1) | 1 (0-1) | 24.1% |
| Acute hepatitis E | 59 (20-121) | 69 (24-142) | 17.8% | 1 (0-2) | 1 (0-2) | −9.3% |
| Leprosy | 26 (12-48) | 6 (3-11) | −76.6% | <0.5 (0-1) | <0.5 (0-0.5) | −82.0% |
| Other infectious diseases | 2886 (1920-4175) | 2864 (1902-4141) | −0.8% | 54 (36-79) | 42 (28-60) | −23.6% |
| Other infectious diseases | 922 (615-1330) | 957 (635-1386) | 3.8% | 17 (12-25) | 14 (9-20) | −20.2% |
| Anaemia due to other infectious diseases | 2000 (1329-2897) | 1947 (1292-2812) | −2.7% | 38 (25-55) | 28 (19-41) | −25.1% |
| Guillain-Barré syndrome due to other infectious diseases | 1 (0-1) | 1 (0-1) | 35.8% | <0.5 (0-0.5) | <0.5 (0-0.5) | 4.5% |
| Non-communicable diseases | 435 400 (365 526-515 063) | 611 076 (512 645-721 956) | 40.3% | 8213(6895-9715) | 8869 (7440-10 478) | 8.0% |
| Neoplasms | 2540 (1876-3348) | 4483 (3324-5861) | 76.5% | 48 (35-63) | 65(48-85) | 35.8% |
| Oesophageal cancer | 61(42-86) | 75 (49-103) | 22.8% | 1 (1-2) | 1(1-1) | −5.5% |
| Stomach cancer | 204 (137-286) | 229 (150-323) | 12.3% | 4(3-5) | 3(2-5) | −13.6% |
| Liver cancer | 77 (53-104) | 140 (96-189) | 82.7% | 1 (1-2) | 2(1-3) | 40.6% |
| Liver cancer secondary to hepatitis B | 35 (23-49) | 64 (43-89) | 81.4% | 1 (0-1) | 1 (1-1) | 39.6% |
| Liver cancer secondary to hepatitis C | 19 (13-27) | 34 (23-47) | 80.5% | <0.5 (0-1) | <0.5 (0-1) | 38.9% |
| Liver cancer secondary to alcohol use | 15 (9-21) | 29 (19-42) | 100.2% | <0.5 (0-0.5) | <0.5 (0-1) | 54.1% |
| Other liver cancer | 8(4-12) | 12 (7-19) | 60.3% | <0.5 (0-0.5) | <0.5 (0-0.5) | 23.3% |
| Larynx cancer | 47 (26-77) | 63 (34-102) | 32.5% | 1 (0-1) | 1 (0-1) | 2.0% |
| Trachea, bronchus, and lung cancers | 227 (154-317) | 355 (234-493) | 56.5% | 4(3-6) | 5 (3-7) | 20.5% |
| Breast cancer | 504 (351-714) | 898 (623-1268) | 78.0% | 10 (7-13) | 13 (9-18) | 37.0% |
| Cervical cancer | 99 (59-146) | 111 (64-160) | 11.8% | 2(1-3) | 2(1-2) | −14.0% |
| Uterine cancer | 47(25-82) | 68 (30-107) | 44.5% | 1 (0-2) | 1 (0-2) | 11.2% |
| Prostate cancer | 165 (109-249) | 464 (298-729) | 181.3% | 3(2-5) | 7 (4-11) | 116.4% |
| Colon and rectum cancers | 307 (223-411) | 564 (408-759) | 83.9% | 6 (4-8) | 8(6-11) | 41.5% |
| Mouth cancer | 63 (44-84) | 101 (71-136) | 61.6% | 1 (1-2) | 1 (1-2) | 24.3% |
| Nasopharynx cancer | 15 (9-23) | 25 (14-39) | 64.1% | <0.5 (0-0.5) | <0.5 (0-1) | 26.3% |
| Cancer of other part of pharynx and oropharynx | 29 (16-42) | 45 (25-67) | 53.3% | 1 (0-1) | 1 (0-1) | 18.0% |
| Gallbladder and biliary tract cancer | 19 (12-29) | 35 (20-53) | 81.2% | <0.5 (0-1) | 1 (0-1) | 39.5% |
| Pancreatic cancer | 23 (15-33) | 37 (23-54) | 59.4% | <0.5 (0-1) | 1 (0-1) | 22.6% |
| Malignant melanoma of skin | 24 (15-40) | 45 (25-74) | 84.5% | <0.5 (0-1) | 1 (0-1) | 42.0% |
| Non-melanoma skin cancer | 115 (85-148) | 255 (192-326) | 122.2% | 2(2-3) | 4(3-5) | 71.0% |
| Ovarian cancer | 41 (27-56) | 63 (39-89) | 53.8% | 1 (1-1) | 1 (1-1) | 18.3% |
| Testicular cancer | 8(4-12) | 12 (7-20) | 64.2% | <0.5 (0-0.5) | <0.5 (0-0.5) | 26.4% |
| Kidney and other urinary organ cancers | 32 (21-48) | 79 (52-118) | 143.4% | 1 (0-1) | 1 (1-2) | 87.3% |
| Bladder cancer | 81 (57-110) | 125 (85-171) | 54.6% | 2(1-2) | 2(1-2) | 18.9% |
| Brain and nervous system cancers | 57 (34-84) | 94 (51-134) | 63.3% | 1 (1-2) | 1(1-2) | 25.6% |
| Thyroid cancer | 21 (13-32) | 48 (28-75) | 132.4% | <0.5 (0-1) | 1 (0-1) | 78.8% |
| Hodgkin's disease | 13 (8-20) | 17 (10-27) | 25.7% | <0.5 (0-0.5) | <0.5 (0-0.5) | −3.3% |
| Non-Hodgkin's lymphoma | 60 (42-80) | 110 (77-147) | 83.5% | 1 (1-2) | 2 (1-2) | 41.2% |
| Multiple myeloma | 22 (13-34) | 36 (21-53) | 64.9% | <0-5 (0-1) | 1 (0-1) | 26.9% |
| Leukaemia | 79 (53-110) | 123 (83-170) | 57.2% | 1 (1-2) | 2(1-2) | 20.9% |
| Other neoplasms | 99 (67-139) | 266 (174-366) | 168.2% | 2(1-3) | 4(3-5) | 106.4% |
| Cardiovascular and circulatory diseases | 14 373 (11 094-18 134) | 21 985 (16 947-27 516) | 53.0% | 271(209-342) | 319 (246-399) | 17.7% |
| Rheumatic heart disease | 1150 (765-1709) | 1430 (944-2067) | 24.3% | 22 (14-32) | 21 (14-30) | −4.4% |
| Valvular disease due to rheumatic heart disease | 861 (477-1429) | 1009 (557-1646) | 17.3% | 16 (9-27) | 15 (8-24) | −9.8% |
| Heart failure due to rheumatic heart disease | 290 (191-412) | 420 (278-592) | 45.1% | 5 (4-8) | 6 (4-9) | 11.6% |
| Ischaemic heart disease | 5952 (3679-8768) | 8795 (5447-12 806) | 47.8% | 112 (69-165) | 128 (79-186) | 13.7% |
| Myocardial infarction due to ischaemic heart disease | 29 (15-45) | 42 (22-67) | 45.5% | 1 (0-1) | 1 (0-1) | 11.9% |
| Angina due to ischaemic heart disease | 5030 (2942-7567) | 7234 (4232-10 986) | 43.8% | 95 (55-143) | 105 (61-159) | 10.7% |
| Heart failure due to ischaemic heart disease | 894 (609-1236) | 1518 (1038-2128) | 69.9% | 17 (11-23) | 22 (15-31) | 30.8% |
| Cerebrovascular disease | 2328 (1864-2837) | 4346 (3476-5298) | 86.7% | 44 (35-54) | 63 (50-77) | 43.6% |
| Ischaemic stroke | 1857 (1489-2263) | 3384 (2705-4121) | 82.2% | 35 (28-43) | 49 (39-60) | 40.2% |
| Ischaemic stroke (acute) | 77 (52-107) | 133 (90-183) | 72.8% | 1(1-2) | 2 (1-3) | 32.9% |
| Ischaemic stroke (chronic) | 1780 (1416-2187) | 3251 (2583-3999) | 82.6% | 34 (27-41) | 47 (37-58) | 40.5% |
| Haemorrhagic and other non-ischaemic stroke | 471(373-585) | 961 (769-1178) | 104.1% | 9 (7-11) | 14 (11-17) | 57.0% |
| Haemorrhagic non-ischaemic stroke (acute) | 28 (18-38) | 56 (37-78) | 104.1% | 1 (0-1) | 1 (1-1) | 57.1% |
| Haemorrhagic non-ischaemic stroke (chronic) | 444 (345-558) | 905 (717-1121) | 104.1% | 8 (7-11) | 13 (10-16) | 57.0% |
| Hypertensive heart disease | 292 (202-412) | 460 (315-639) | 57.4% | 6 (4-8) | 7 (5-9) | 21.1% |
| Cardiomyopathy and myocarditis | 272 (183-378) | 394 (269-551) | 44.8% | 5 (3-7) | 6 (4-8) | 11.4% |
| Acute myocarditis | 1 (0-1) | 1 (0-1) | 30.9% | <0.5 (0-0.5) | <0.5 (0-0.5) | 0.7% |
| Heart failure due to cardiomyopathy and myocarditis | 271 (182-378) | 393 (268-551) | 44.8% | 5 (3-7) | 6 (4-8) | 11.4% |
| Atrial fibrillation and flutter | 1433 (970-1987) | 2425 (1631-3382) | 69.2% | 27 (18-37) | 35 (24-49) | 30.2% |
| Peripheral vascular disease | 256 (132-453) | 419 (218-744) | 63.7% | 5 (2-9) | 6 (3-11) | 26.0% |
| Endocarditis | 42 (28-60) | 62 (42-87) | 46.1% | 1 (1-1) | 1 (1-1) | 12.4% |
| Endocarditis | <0.5 (0-1) | 1 (0-1) | 87.7% | <0.5 (0-0.5) | <0.5 (0-0.5) | 44.4% |
| Heart failure due to endocarditis | 42 (28-59) | 61 (42-87) | 45.8% | 1 (1-1) | 1 (1-1) | 12.2% |
| Other cardiovascular and circulatory diseases | 2646 (1448-4148) | 3655(2053-5581) | 38.1% | 50 (27-78) | 53 (30-81) | 6.3% |
| Heart failure due to other circulatory diseases | 183 (123-259) | 268 (180-372) | 46.3% | 3 (2-5) | 4 (3-5) | 12.6% |
| Other cardiovascular and circulatory diseases | 2463 (1271-3992) | 3388 (1783-5346) | 37.5% | 46 (24-75) | 49 (26-78) | 5.8% |
| Chronic respiratory diseases | 34 976 (24 536-47 579) | 49 303 (33 874-67 087) | 41.0% | 660 (463-897) | 716 (492-974) | 8.5% |
| Chronic obstructive pulmonary disease | 20 097 (13 793-28 248) | 29 373 (19 850-41 822) | 46.2% | 379 (260-533) | 426 (288-607) | 12.5% |
| Chronic obstructive pulmonary disease | 19 805 (13 571-27 835) | 28 893 (19 455-41 183) | 45.9% | 374 (256-525) | 419 (282-598) | 12.3% |
| Heart failure due to chronic obstructive pulmonary disease | 292 (195-410) | 480 (316-678) | 64.1% | 6 (4-8) | 7 (5-10) | 26.3% |
| Pneumoconiosis | 212 (104-477) | 445 (193-1377) | 109.9% | 4(2-9) | 6(3-20) | 61.5% |
| Silicosis | 76 (22-199) | 136 (38-408) | 79.8% | 1 (0-4) | 2 (1-6) | 38.3% |
| Asbestosis | 44 (4-253) | 130(8-974) | 192.4% | 1(0-5) | 2 (0-14) | 125.0% |
| Coal workers' pneumoconiosis | 24 (10-43) | 33 (13-64) | 41.1% | <0.5 (0-1) | <0.5 (0-1) | 8.6% |
| Other pneumoconiosis | 43 (12-108) | 101 (26-261) | 135.2% | 1(0-2) | 1 (0-4) | 80.9% |
| Heart failure due to pneumoconiosis | 25 (17-36) | 45 (31-63) | 77.1% | <0.5 (0-1) | 1 (0-1) | 36.3% |
| Asthma | 10 835 (7247-15 268) | 13 835 (9286-19 487) | 27.7% | 204 (137-288) | 201 (135-283) | −1.7% |
| Interstitial lung disease and pulmonary sarcoidosis | 111 (68-182) | 162 (99-268) | 45.8% | 2(1-3) | 2 (1-4) | 12.2% |
| Interstitial lung disease and pulmonary sarcoidosis | 69 (37-134) | 99 (52-191) | 44.6% | 1(1-3) | 1 (1-3) | 11.3% |
| Heart failure due to interstitial lung disease and pulmonary sarcoidosis | 42 (28-60) | 62 (42-90) | 47.9% | 1 (1-1) | 1 (1-1) | 13.8% |
| Other chronic respiratory diseases | 3722 (2529-5177) | 5488 (3773-7675) | 47.5% | 70 (48-98) | 80 (55-111) | 13.5% |
| Cirrhosis of the liver | 455 (309-630) | 613 (415-862) | 34.8% | 9 (6-12) | 9(6-13) | 3.7% |
| Cirrhosis of the liver secondary to hepatitis B | 156 (93-235) | 198 (120-298) | 26.7% | 3 (2-4) | 3 (2-4) | −2.5% |
| Cirrhosis of the liver secondary to hepatitis C | 113 (67-170) | 155(93-235) | 37.5% | 2 (1-3) | 2(1-3) | 5.8% |
| Cirrhosis of the liver secondary to alcohol use | 109 (65-163) | 160 (94-241) | 46.6% | 2 (1-3) | 2(1-3) | 12.8% |
| Other cirrhosis of the liver | 77(46-118) | 101 (61-150) | 30.2% | 1(1-2) | 1 (1-2) | 0.2% |
| Digestive diseases (except cirrhosis) | 4467 (3265-5979) | 5473 (3916-7380) | 22.5% | 84 (62-113) | 79 (57-107) | −5.7% |
| Peptic ulcer disease | 355 (224-570) | 311 (196-485) | −12.3% | 7 (4-11) | 5 (3-7) | −32.5% |
| Peptic ulcer disease | 190 (111-328) | 154 (93-254) | −18.8% | 4(2-6) | 2 (1-4) | −37.5% |
| Anaemia due to peptic ulcer disease | 165(89-325) | 157 (87-273) | −4.8% | 3(2-6) | 2 (1-4) | −26.7% |
| Gastritis and duodenitis | 820 (498-1253) | 855 (525-1386) | 4.2% | 15 (9-24) | 12 (8-20) | −19.8% |
| Gastritis and duodenitis | 178 (120-259) | 182 (121-264) | 2.3% | 3(2-5) | 3 (2-4) | −21.3% |
| Anaemia due to gastritis and duodenitis | 642 (368-1046) | 673 (389-1174) | 4.7% | 12 (7-20) | 10(6-17) | −19.4% |
| Appendicitis | 154 (99-226) | 176 (112-257) | 14.3% | 3 (2-4) | 3 (2-4) | −12.0% |
| Paralytic ileus and intestinal obstruction without hernia | 10 (4-24) | 12 (6-27) | 24.4% | <0.5 (0-0.5) | <0.5 (0-0.5) | −4.2% |
| Inguinal or femoral hernia | 333 (144-689) | 441 (189-861) | 32.5% | 6(3-13) | 6(3-12) | 1.9% |
| Non-infective inflammatory bowel disease | 1582 (1130-2151) | 1795 (1272-2460) | 13.5% | 30 (21-41) | 26 (18-36) | −12.7% |
| Non-infective inflammatory bowel disease due to ulcerative colitis | 932 (583-1492) | 1169 (734-1801) | 25.4% | 18 (11-28) | 17 (11-26) | −3.5% |
| Non-infective inflammatory bowel disease due to Crohn's disease | 541 (356-775) | 513 (334-733) | −5.2% | 10 (7-15) | 7 (5-11) | −27.0% |
| Non-infective inflammatory bowel disease severe episodes due to ulcerative colitis | 54 (32-89) | 64 (39-102) | 18.6% | 1 (1-2) | 1(1-1) | −8.7% |
| Non-infective inflammatory bowel disease severe episodes due to Crohn's disease | 54 (31-91) | 50 (30-81) | −8.5% | 1 (1-2) | 1 (0-1) | −29.6% |
| Vascular disorders of intestine | 6 (4-10) | 14 (8-20) | 121.6% | <0.5 (0-0.5) | <0.5 (0-0.5) | 70.5% |
| Gallbladder and bile duct disease | 314 (215-440) | 453 (310-635) | 44.6% | 6 (4-8) | 7 (4-9) | 11.2% |
| Pancreatitis | 133 (85-198) | 206 (131-303) | 54.9% | 3 (2-4) | 3 (2-4) | 19.2% |
| Other digestive diseases | 761 (553-1025) | 1209 (852-1638) | 58.9% | 14 (10-19) | 18 (12-24) | 22.3% |
| Neurological disorders | 29 389 (23 635-35 837) | 42 943 (34 605-52 115) | 46.1% | 554(446-676) | 623(502-756) | 12.4% |
| Alzheimer's disease and other dementias | 3785 (2720-5007) | 6801 (4898-9043) | 79.7% | 71 (51-94) | 99 (71-131) | 38.3% |
| Parkinson's disease | 356 (231-560) | 606 (396-964) | 70.5% | 7 (4-11) | 9(6-14) | 31.2% |
| Epilepsy | 6415 (4993-7799) | 8740 (6762-10 594) | 36.2% | 121 (94-147) | 127 (98-154) | 4.8% |
| Multiple sclerosis | 373 (276-473) | 524 (379-660) | 40.8% | 7 (5-9) | 8 (5-10) | 8.3% |
| Migraine | 15 927 (10 394-22 023) | 22 362 (14 395-31 121) | 40.4% | 300 (196-415) | 325(209-452) | 8.0% |
| Tension-type headache | 1266 (754-2016) | 1779 (1056-2822) | 40.5% | 24 (14-38) | 26 (15-41) | 8.1% |
| Other neurological disorders | 1267 (958-1616) | 2129 (1619-2723) | 68.0% | 24 (18-30) | 31(23-40) | 29.3% |
| Other neurological disorders | 1399 (1056-1789) | 2353 (1785-3011) | 68.2% | 26 (20-34) | 34 (26-44) | 29.4% |
| Guillain-Barre syndrome due to other neurological disorders | 2 (1-3) | 3 (2-4) | 35.6% | <0.5 (0-0.5) | <0.5 (0-0.5) | 4.4% |
| Mental and behavioural disorders | 129 377 (106 771-154 032) | 176 626 (145 613-209 122) | 36.5% | 2440 (2014-2905) | 2564 (2113-3035) | 5.0% |
| Schizophrenia | 9760 (6186-13 369) | 14 400 (9160-19 752) | 47.5% | 184 (117-252) | 209 (133-287) | 13.5% |
| Alcohol use disorders | 10 470 (7173-14 644) | 13 826 (9248-19 212) | 32.1% | 197 (135-276) | 201 (134-279) | 1.6% |
| Alcohol dependence | 10 385 (7086-14 556) | 13 735 (9164-19 108) | 32.3% | 196 (134-275) | 199 (133-277) | 1.8% |
| Fetal alcohol syndrome | 85 (49-133) | 91 (55-138) | 6.9% | 2(1-3) | 1 (1-2) | −17.7% |
| Drug use disorders | 11 764 (8388-15 468) | 16 412 (11 836-21 583) | 39.5% | 222 (158-292) | 238 (172-313) | 7.3% |
| Opioid use disorders | 4812 (3350-6281) | 7170 (5143-9257) | 49.0% | 91 (63-118) | 104 (75-134) | 14.6% |
| Cocaine use disorders | 800 (475-1214) | 1085 (633-1639) | 35.7% | 15 (9-23) | 16 (9-24) | 4.4% |
| Amphetamine use disorders | 1894 (1067-2955) | 2596 (1460-3957) | 37.1% | 36 (20-56) | 38 (21-57) | 5.5% |
| Cannabis use disorders | 1693 (1105-2418) | 2057 (1348-2929) | 21.5% | 32 (21-46) | 30 (20-43) | −6.5% |
| Other drug use disorders | 2565 (1583-3817) | 3503 (2108-5170) | 36.6% | 48 (30-72) | 51 (31-75) | 5.1% |
| Unipolar depressive disorders | 54 010 (40 381-68 450) | 74 264 (55 670-94 240) | 37.5% | 1019 (762-1291) | 1078 (808-1368) | 5.8% |
| Major depressive disorder | 46 139 (34 517-58 427) | 63 179 (47 779-80 891) | 36.9% | 870 (651-1102) | 917 (693-1174) | 5.4% |
| Dysthymia | 7871 (5266-10 858) | 11 084 (7297-15 447) | 40.8% | 148 (99-205) | 161 (106-224) | 8.4% |
| Bipolar affective disorder | 9129 (5757-13 169) | 12 867 (8084-18 654) | 40.9% | 172 (109-248) | 187 (117-271) | 8.5% |
| Anxiety disorders | 19 664 (13 868-26 820) | 26 826 (18 779-36 795) | 36.4% | 371(262-506) | 389 (273-534) | 5.0% |
| Eating disorders | 1120 (749-1554) | 1956 (1316-2742) | 74.6% | 21 (14-29) | 28 (19-40) | 34.3% |
| Anorexia nervosa | 95 (65-136) | 188 (125-265) | 97.1% | 2(1-3) | 3 (2-4) | 51.7% |
| Bulimia nervosa | 1025 (687-1417) | 1768 (1183-2480) | 72.5% | 19 (13-27) | 26 (17-36) | 32.7% |
| Pervasive development disorders | 5918 (4133-8130) | 7666 (5355-10 565) | 29.5% | 112 (78-153) | 111 (78-153) | −0.3% |
| Autism | 3088 (2119-4260) | 4007 (2752-5563) | 29.8% | 58 (40-80) | 58 (40-81) | −0.2% |
| Asperger's syndrome | 2830 (1917-4016) | 3659 (2463-5150) | 29.3% | 53 (36-76) | 53 (36-75) | −0.5% |
| Childhood behavioural disorders | 5472 (3277-8359) | 6245 (3785-9347) | 14.1% | 103 (62-158) | 91 (55-136) | −12.2% |
| Attention-deficit hyperactivity disorder | 424 (244-667) | 491(280-775) | 15.8% | 8 (5-13) | 7 (4-11) | −10.9% |
| Conduct disorder | 5047 (2960-7840) | 5753 (3428-8748) | 14.0% | 95 (56-148) | 84 (50-127) | −12.3% |
| Idiopathic intellectual disability | 1247 (746-1924) | 1043 (572-1687) | −16.4% | 24 (14-36) | 15 (8-24) | −35.7% |
| Other mental and behavioural disorders | 822 (485-1307) | 1121 (661-1774) | 36.4% | 16 (9-25) | 16 (10-26) | 5.0% |
| Diabetes, urogenital, blood, and endocrine diseases | 38 626 (28 236-51 159) | 56 924 (42 172-75 399) | 47.4% | 729 (533-965) | 826 (612-1094) | 13.4% |
| Diabetes mellitus | 12 412 (8403-17 524) | 20 758 (14 415-28 762) | 67.2% | 234 (158-331) | 301 (209-417) | 28.7% |
| Uncomplicated diabetes mellitus | 4260 (2420-6828) | 6569 (3684-10 380) | 54.2% | 80 (46-129) | 95 (53-151) | 18.7% |
| Diabetic foot | 209 (108-356) | 308 (160-518) | 47.1% | 4 (2-7) | 4(2-8) | 13.2% |
| Diabetic neuropathy | 7325 (4967-10 520) | 11 914 (7977-17 035) | 62.6% | 138 (94-198) | 173 (116-247) | 25.2% |
| Amputation due to diabetes mellitus | 392 (192-669) | 905 (481-1427) | 130.9% | 7 (4-13) | 13 (7-21) | 77.6% |
| Vision loss due to diabetes mellitus | 227 (166-307) | 1062 (795-1395) | 368.6% | 4 (3-6) | 15 (12-20) | 260.6% |
| Acute glomerulonephritis | 1 (0-2) | 1 (0-2) | 1.6% | <0.5 (0-0.5) | <0.5 (0-0.5) | −21.8% |
| Chronic kidney diseases | 2558 (1900-3288) | 4018 (2972-5204) | 57.1% | 48 (36-62) | 58 (43-76) | 20.9% |
| Chronic kidney disease due to diabetes mellitus | 621 (453-796) | 1003 (740-1317) | 61.5% | 12 (9-15) | 15 (11-19) | 24.2% |
| Stage IV chronic kidney disease due to diabetes mellitus | 88 (58-126) | 141 (94-205) | 60.5% | 2(1-2) | 2(1-3) | 23.5% |
| End-stage renal disease due to diabetes mellitus | 388 (270-506) | 626 (436-817) | 61.5% | 7 (5-10) | 9(6-12) | 24.2% |
| Anaemia due to chronic kidney disease stage III from diabetes mellitus | 145 (79-237) | 235 (126-378) | 62.0% | 3 (1-4) | 3(2-5) | 24.7% |
| Chronic kidney disease due to hypertension | 550 (411-711) | 872 (645-1123) | 58.4% | 10 (8-13) | 13 (9-16) | 21.9% |
| Stage IV chronic kidney disease due to hypertension | 88 (59-128) | 138 (93-198) | 56.7% | 2(1-2) | 2(1-3) | 20.6% |
| End-stage renal disease due to hypertension | 326 (225-422) | 515(359-670) | 58.0% | 6 (4-8) | 7(5-10) | 21.6% |
| Anaemia due to chronic kidney disease stage III from hypertension | 136 (77-222) | 219 (124-354) | 60.6% | 3 (1-4) | 3(2-5) | 23.6% |
| Chronic kidney disease unspecified | 1386 (1032-1800) | 2143(1585-2779) | 54.6% | 26 (19-34) | 31(23-40) | 19.0% |
| Stage IV unspecified or other chronic kidney disease | 229 (154-335) | 352 (233-506) | 53.9% | 4(3-6) | 5 (3-7) | 18.4% |
| End-stage renal disease from unspecified or other chronic kidney disease | 799 (555-1042) | 1242 (872-1607) | 55.5% | 15 (10-20) | 18 (13-23) | 19.6% |
| Anaemia due to unspecified or other chronic kidney disease stage III | 359 (208-579) | 549 (314-889) | 53.1% | 7 (4-11) | 8(5-13) | 17.8% |
| Urinary diseases and male infertility | 4651 (3057-7025) | 8188 (5398-11 978) | 76.0% | 88 (58-133) | 119 (78-174) | 35.5% |
| Tubulointerstitial nephritis, pyelonephritis, and urinary tract infections | 156 (84-269) | 207 (109-360) | 33.2% | 3 (2-5) | 3(2-5) | 2.5% |
| Urolithiasis | 480 (306-842) | 716 (447-1425) | 49.1% | 9 (6-16) | 10 (6-21) | 14.7% |
| Urolithiasis episodes | 204 (107-526) | 225 (104-918) | 10.5% | 4 (2-10) | 3(2-13) | −15.0% |
| Chronic urolithiasis | 277 (156-443) | 491(276-785) | 77.5% | 5 (3-8) | 7 (4-11) | 36.6% |
| Benign prostatic hyperplasia | 3726 (2392-5645) | 6834 (4377-10 179) | 83.4% | 70 (45-106) | 99 (64-148) | 41.1% |
| Male infertility | 126 (50-270) | 173 (70-365) | 36.9% | 2 (1-5) | 3(1-5) | 5.3% |
| Other urinary diseases | 162 (103-267) | 258 (167-415) | 58.8% | 3 (2-5) | 4(2-6) | 22.2% |
| Gynaecological diseases | 7671(4880-11715) | 10 042(6226-15619) | 30.9% | 145 (92-221) | 146 (90-227) | 0.7% |
| Uterine fibroids | 2341 (1568-3340) | 3037 (1967-4551) | 29.7% | 44 (30-63) | 44 (29-66) | −0.2% |
| Uterine fibroids | 934 (401-1852) | 1527(664-3059) | 63.5% | 18 (8-35) | 22 (10-44) | 25.8% |
| Anaemia due to uterine fibroids | 1407 (943-2023) | 1509 (1000-2199) | 7.3% | 27 (18-38) | 22 (15-32) | −17.4% |
| Polycystic ovarian syndrome | 2027 (971-3786) | 2756 (1312-5212) | 35.9% | 38 (18-71) | 40 (19-76) | 4.6% |
| Polycystic ovarian syndrome | 1982 (931-3747) | 2694 (1245-5171) | 35.9% | 37 (18-71) | 39 (18-75) | 4.6% |
| Infertility due to polycystic ovarian syndrome | 45 (18-95) | 62 (25-128) | 37.5% | 1(0-2) | 1 (0-2) | 5.8% |
| Female infertility | 91 (36-189) | 125 (50-259) | 37.6% | 2 (1-4) | 2 (1-4) | 5.9% |
| Endometriosis | 404 (142-738) | 544 (188-1007) | 34.6% | 8 (3-14) | 8(3-15) | 3.5% |
| Endometriosis | 388 (129-715) | 522 (166-974) | 34.4% | 7 (2-13) | 8(2-14) | 3.4% |
| Infertility due to endometriosis | 16(6-35) | 22 (9-46) | 37.8% | <0.5 (0-1) | <0.5 (0-1) | 6.0% |
| Genital prolapse | 1339 (544-2686) | 1811 (741-3649) | 35.2% | 25 (10-51) | 26 (11-53) | 4.1% |
| Premenstrual syndrome | 983 (49-2592) | 1249 (63-3337) | 27.0% | 19 (1-49) | 18 (1-48) | −2.3% |
| Other gynaecological diseases | 485 (330-703) | 520 (345-759) | 7.3% | 9(6-13) | 8 (5-11) | −17.4% |
| Haemoglobinopathies and haemolytic anaemias | 8271 (5746-11276) | 10 197 (7166-13 843) | 23.3% | 156 (108-213) | 148 (104-201) | −5.1% |
| Thalassaemias | 3725 (2499-5279) | 4636 (3098-6621) | 24.4% | 70 (47-100) | 67(45-96) | −4.2% |
| β-thalassaemia major | 31 (17-56) | 33 (19-59) | 7.9% | 1 (0-1) | <0.5 (0-1) | −16.9% |
| Haemoglobin E/β-thalassaemia | 22 (14-34) | 24 (15-37) | 8.8% | <0.5 (0-1) | <0.5 (0-1) | −16.3% |
| Haemoglobin H/β-thalassaemia | 10 (6-16) | 10 (6-16) | 3.7% | <0.5 (0-0.5) | <0.5 (0-0.5) | −20.2% |
| Anaemia due to thalassaemias | 3653 (2427-5219) | 4557(3024-6530) | 24.7% | 69 (46-98) | 66 (44-95) | −4.0% |
| Heart failure due to thalassaemias | 10 (6-14) | 13 (8-19) | 34.1% | <0.5 (0-0.5) | <0.5 (0-0.5) | 3.2% |
| Sickle cell disorders | 2647 (1829-3615) | 3665 (2612-4949) | 38.5% | 50 (34-68) | 53 (38-72) | 6.5% |
| Homozygous sickle cell and severe sickle cell/β-thalassaemia | 334 (238-441) | 546 (389-736) | 63.8% | 6 (4-8) | 8(6-11) | 26.1% |
| Haemoglobin sickle cell disorders | 78 (54-107) | 130 (88-182) | 65.5% | 1 (1-2) | 2(1-3) | 27.3% |
| Mild sickle cell/β-thalassaemia | 26 (18-37) | 38 (27-53) | 43.8% | <0.5 (0-1) | 1 (0-1) | 10.6% |
| Anaemia due to sickle cell disorders | 2211 (1439-3181) | 2954 (1957-4240) | 33.6% | 42 (27-60) | 43 (28-62) | 2.8% |
| G6PD deficiency | 120 (81-174) | 146 (97-210) | 22.1% | 2(2-3) | 2(1-3) | −6.1% |
| Anaemia due to G6PD deficiency | 116 (77-171) | 141(93-205) | 21.5% | 2(1-3) | 2(1-3) | −6.5% |
| Heart failure due to G6PD deficiency | 4 (2-6) | 5(3-8) | 40.2% | <0.5 (0-0.5) | <0.5 (0-0.5) | 7.8% |
| Other haemoglobinopathies and haemolytic anaemias | 1779 (1193-2565) | 1750 (1171-2503) | −1.6% | 34 (23-48) | 25 (17-36) | −24.3% |
| Anaemia due to other haemoglobinopathies and haemolytic anaemias | 1757 (1173-2545) | 1720 (1138-2483) | −2.1% | 33 (22-48) | 25 (17-36) | −24.7% |
| Heart failure due to other haemoglobinopathies and haemolytic anaemias | 22 (14-32) | 31(20-45) | 39.5% | <0.5 (0-1) | <0.5 (0-1) | 7.4% |
| Other endocrine, nutritional, blood, and immune disorders | 3063 (2256-4177) | 3721 (2713-5114) | 21.5% | 58 (43-79) | 54 (39-74) | −6.5% |
| Other endocrine, nutritional, blood, and immune disorders | 1254 (739-1952) | 1919 (1133-2991) | 53.0% | 24 (14-37) | 28 (16-43) | 17.7% |
| Anaemia due to other endocrine, nutritional, blood, and immune disorders | 1777 (1187-2562) | 1756 (1166-2542) | −1.2% | 34 (22-48) | 25 (17-37) | −23.9% |
| Heart failure due to other endocrine, nutritional, blood, and immune disorders | 33 (22-47) | 48 (33-69) | 46.1% | 1 (0-1) | 1 (0-1) | 12.4% |
| Musculoskeletal disorders | 114 719 (87 053-145 247) | 165 955 (126 364-208 779) | 44.7% | 2164 (1642-2740) | 2409 (1834-3030) | 11.3% |
| Rheumatoid arthritis | 2566 (1831-3381) | 3776 (2672-4954) | 47.1% | 48 (35-64) | 55(39-72) | 13.2% |
| Osteoarthritis | 10 449 (7100-14 788) | 17 135 (11 884-24 256) | 64.0% | 197 (134-279) | 249 (172-352) | 26.2% |
| Osteoarthritis of the hip | 1821 (1200-2616) | 2917 (1945-4389) | 60.2% | 34 (23-49) | 42 (28-64) | 23.2% |
| Osteoarthritis of the knee | 8627 (5929-12 276) | 14 218 (9809-19 968) | 64.8% | 163 (112-232) | 206 (142-290) | 26.8% |
| Low back and neck pain | 82 111 (56 962-110 433) | 116 704 (80 615-156 527) | 42.1% | 1549 (1074-2083) | 1694 (1170-2272) | 9.4% |
| Low back pain | 58 245 (39 934-78 139) | 83 063 (56 632-111 880) | 42.6% | 1099 (753-1474) | 1206 (822-1624) | 9.7% |
| Neck pain | 23 866 (16 535-33 105) | 33 640 (23 469-46 476) | 41.0% | 450 (312-624) | 488 (341-675) | 8.5% |
| Gout | 76 (48-112) | 114 (72-167) | 49.3% | 1 (1-2) | 2(1-2) | 14.9% |
| Other musculoskeletal disorders | 19 517 (16 148-22 127) | 28 226 (23 201-31 884) | 44.6% | 368 (305-417) | 410 (337-463) | 11.3% |
| Other non-communicable diseases | 66 478 (45 586-97 937) | 86 771 (59 561-128 605) | 30.5% | 1254 (860-1847) | 1259 (864-1867) | 0.4% |
| Congenital anomalies | 2620(2088-3333) | 3279 (2594-4167) | 25.2% | 49 (39-63) | 48 (38-60) | −3.7% |
| Neural tube defects | 569 (330-901) | 754 (439-1142) | 32.6% | 11 (6-17) | 11 (6-17) | 2.0% |
| Congenital heart anomalies | 498 (350-711) | 563 (388-804) | 13.0% | 9 (7-13) | 8(6-12) | −13.0% |
| Congenital heart anomalies | 189 (86-354) | 226 (103-425) | 19.1% | 4 (2-7) | 3 (1-6) | −8.3% |
| Heart failure due to congenital heart anomalies | 308 (203-442) | 337 (221-486) | 9.3% | 6 (4-8) | 5 (3-7) | −15.9% |
| Ccenter lip and ccenter palate | 259 (180-362) | 254 (181-346) | −1.7% | 5 (3-7) | 4(3-5) | −24.4% |
| Down's syndrome | 462 (306-664) | 627 (425-888) | 35.7% | 9(6-13) | 9(6-13) | 4.4% |
| Other chromosomal abnormalities | 191 (127-274) | 276 (182-392) | 44.1% | 4(2-5) | 4(3-6) | 10.8% |
| Turner syndrome | 3 (1-6) | 4(2-8) | 35.6% | <0.5 (0-0.5) | <0.5 (0-0.5) | 4.3% |
| Klinefelter syndrome | 5 (2-10) | 6 (3-14) | 38.7% | <0.5 (0-0.5) | <0.5 (0-0.5) | 6.8% |
| Chromosomal unbalanced rearrangements | 184 (123-261) | 265 (176-377) | 44.3% | 3(2-5) | 4 (3-5) | 11.1% |
| Other congenital anomalies | 642 (464-868) | 806 (596-1053) | 25.6% | 12 (9-16) | 12 (9-15) | −3.3% |
| Other congenital anomalies | 437 (325-580) | 595 (446-775) | 36.4% | 8 (6-11) | 9 (6-11) | 4.9% |
| Hearing loss due to other congenital anomalies | 225 (142-336) | 240 (152-363) | 6.6% | 4 (3-6) | 3 (2-5) | −17.9% |
| Skin and subcutaneous diseases | 26 273 (16 798-40 932) | 33 744 (21 503-52 280) | 28.4% | 496 (317-772) | 490 (312-759) | −1.2% |
| Eczema | 6890 (3508-10 872) | 8897 (4518-14 049) | 29.1% | 130 (66-205) | 129 (66-204) | −0.6% |
| Psoriasis | 742 (371-1179) | 1059 (528-1690) | 42.8% | 14 (7-22) | 15 (8-25) | 9.8% |
| Cellulitis | 302 (126-648) | 376 (163-831) | 24.5% | 6 (2-12) | 5(2-12) | −4.2% |
| Abscess, impetigo, and other bacterial skin diseases | 1038 (473-2016) | 1322 (599-2511) | 27.4% | 20(9-38) | 19 (9-36) | −1.9% |
| Impetigo | 871 (417-1624) | 1088 (514-2048) | 24.9% | 16 (8-31) | 16 (7-30) | −3.9% |
| Abscess and other bacterial skin diseases cases | 167 (54-386) | 235 (78-539) | 40.8% | 3 (1-7) | 3(1-8) | 8.3% |
| Scabies | 1881 (956-3384) | 1580 (807-2792) | −16.0% | 35 (18-64) | 23 (12-41) | −35.4% |
| Fungal skin diseases | 1618 (532-3754) | 2303 (740-5435) | 42.3% | 31 (10-71) | 33 (11-79) | 9.5% |
| Viral skin diseases | 2354(1058-4369) | 2731(1203-4941) | 16.0% | 44 (20-82) | 40 (17-72) | −10.7% |
| Molluscum contagiosum | 289 (88-702) | 270(85-645) | −6.6% | 5(2-13) | 4 (1-9) | −28.1% |
| Viral warts | 2065 (816-3960) | 2461 (984-4720) | 19.2% | 39 (15-75) | 36 (14-69) | −8.3% |
| Acne vulgaris | 3281 (1545-6205) | 4002 (1869-7575) | 22.0% | 62 (29-117) | 58 (27-110) | −6.2% |
| Alopecia areata | 1002 (313-1906) | 1352 (424-2567) | 35.0% | 19 (6-36) | 20 (6-37) | 3.9% |
| Pruritus | 1433 (682-2676) | 2086 (1004-3951) | 45.6% | 27 (13-50) | 30 (15-57) | 12.1% |
| Urticaria | 1968 (757-3431) | 2600 (980-4441) | 32.1% | 37 (14-65) | 38 (14-64) | 1.6% |
| Decubitus ulcer | 320 (165-524) | 476 (237-779) | 48.8% | 6 (3-10) | 7 (3-11) | 14.5% |
| Other skin and subcutaneous diseases | 3445 (1638-6437) | 4961 (2324-9239) | 44.0% | 65 (31-121) | 72 (34-134) | 10.8% |
| Sense organ diseases | 25 169 (18 140-35 220) | 34 733 (25 167-47 663) | 38.0% | 475 (342-664) | 504 (365-692) | 6.2% |
| Glaucoma | 443 (338-561) | 943 (725-1178) | 112.7% | 8(6-11) | 14 (11-17) | 63.7% |
| Cataracts | 4225 (3283-5364) | 4732 (3647-6010) | 12.0% | 80 (62-101) | 69 (53-87) | −13.8% |
| Macular degeneration | 513 (388-647) | 1329 (1026-1668) | 158.9% | 10 (7-12) | 19 (15-24) | 99.2% |
| Refraction and accommodation disorders | 3608 (2688-4762) | 5593 (4117-7468) | 55.0% | 68 (51-90) | 81 (60-108) | 19.3% |
| Other hearing loss | 12 211 (7258-19 495) | 15 761 (9455-25 210) | 29.1% | 230 (137-368) | 229 (137-366) | −0.7% |
| Other vision loss | 4069 (2171-7180) | 6240(3260-11208) | 53.4% | 77 (41-135) | 91(47-163) | 18.0% |
| Other sense organ diseases | 100 (34-231) | 136 (46-309) | 35.4% | 2 (1-4) | 2 (1-4) | 4.2% |
| Oral disorders | 12 417 (6824-20 984) | 15 015 (7795-26 482) | 20.9% | 234 (129-396) | 218 (113-384) | −7.0% |
| Dental caries | 3704 (1523-7150) | 4984(2086-9356) | 34.5% | 70 (29-135) | 72 (30-136) | 3.5% |
| Dental caries of baby teeth | 403 (164-774) | 425 (172-818) | 5.7% | 8 (3-15) | 6(3-12) | −18.7% |
| Dental caries of permanent teeth | 3302 (1347-6455) | 4559 (1907-8554) | 38.1% | 62 (25-122) | 66 (28-124) | 6.2% |
| Periodontal disease | 3440 (1310-7305) | 5410 (2051-11 286) | 57.3% | 65 (25-138) | 79 (30-164) | 21.0% |
| Edentulism | 5273 (3100-8127) | 4621 (2678-7296) | −12.4% | 99 (58-153) | 67 (39-106) | −32.6% |
| Injuries | 34 068 (24 209-47 034) | 47162 (32 958-66 050) | 38.4% | 643 (457-887) | 685 (478-959) | 6.5% |
| Transport injuries | 12062 (8524-16826) | 16 268 (11 304-22 717) | 34.9% | 228 (161-317) | 236 (164-330) | 3.8% |
| Road injury | 10 363 (7315-14 487) | 13 485 (9362-18 950) | 30.1% | 195 (138-273) | 196 (136-275) | 0.1% |
| Pedestrian injury by road vehicle | 3106 (2183-4360) | 4520 (3139-6367) | 45.6% | 59 (41-82) | 66(46-92) | 12.0% |
| Pedal cycle vehicle | 755 (536-1056) | 1025 (714-1436) | 35.7% | 14 (10-20) | 15 (10-21) | 4.4% |
| Motorised vehicle with two wheels | 1750 (1234-2435) | 2224 (1529-3133) | 27.1% | 33 (23-46) | 32 (22-45) | −2.2% |
| Motorised vehicle with three or more wheels | 4138 (2901-5793) | 5792 (4041-8114) | 40.0% | 78 (55-109) | 84 (59-118) | 7.7% |
| Road injury other | 1440 (1 013-2 020) | 1196 (824-1673) | −16.9% | 27 (19-38) | 17 (12-24) | −36.1% |
| Other transport injury | 1699 (1184-2386) | 2783 (1902-3872) | 63.8% | 32(22-45) | 40(28-56) | 26.0% |
| Unintentional injuries other than transport injuries | 19 036 (13 233-26 794) | 26 620 (18 472-37 641) | 39.8% | 359 (250-505) | 386 (268-546) | 7.6% |
| Falls | 13 324 (9110-18 725) | 19 459 (13 559-27 481) | 46.0% | 251(172-353) | 282 (197-399) | 12.4% |
| Drowning | 233 (161-326) | 281 (191-391) | 20.9% | 4 (3-6) | 4(3-6) | −7.0% |
| Fire, heat, and hot substances | 1010 (637-1575) | 1398 (857-2232) | 38.4% | 19 (12-30) | 20 (12-32) | 6.5% |
| Poisonings | 323(210-470) | 417(276-621) | 29.3% | 6 (4-9) | 6(4-9) | −0.5% |
| Exposure to mechanical forces | 922 (599-1387) | 1021 (662-1490) | 10.8% | 17 (11-26) | 15 (10-22) | −14.7% |
| Mechanical forces (firearm) | 526 (346-784) | 467 (305-676) | −11.2% | 10 (7-15) | 7(4-10) | −31.7% |
| Mechanical forces (other) | 710 (460-1074) | 910 (588-1336) | 28.2% | 13 (9-20) | 13(9-19) | −1.3% |
| Adverse effects of medical treatment | 585 (401-824) | 1088 (727-1537) | 85.9% | 11 (8-16) | 16 (11-22) | 43.1% |
| Animal contact | 437 (293-634) | 234 (154-329) | −46.4% | 8 (6-12) | 3(2-5) | −58.7% |
| Animal contact (venomous) | 355 (233-526) | 168 (110-242) | −52.5% | 7 (4-10) | 2 (2-4) | −63.4% |
| Animal contact (non-venomous) | 82 (55-119) | 66 (44-93) | −20.0% | 2(1-2) | 1 (1-1) | −38.4% |
| Unintentional injuries not classified elsewhere | 2202 (1484-3108) | 2720 (1866-3827) | 23.5% | 42 (28-59) | 39 (27-56) | −4.9% |
| Self-harm and interpersonal violence | 1571(1066-2188) | 1985 (1366-2726) | 26.4% | 30 (20-41) | 29 (20-40) | −2.8% |
| Self-harm | 308 (209-428) | 407 (278-577) | 32.3% | 6 (4-8) | 6 (4-8) | 1.8% |
| Interpersonal violence | 1263 (840-1775) | 1578 (1085-2180) | 24.9% | 24 (16-33) | 23(16-32) | −3.9% |
| Assault by firearm | 504 (336-714) | 587(404-808) | 16.5% | 10 (6-13) | 9(6-12) | −10.4% |
| Assault by sharp object | 368 (245-516) | 540 (369-743) | 46.8% | 7(5-10) | 8 (5-11) | 12.9% |
| Assault by other means | 543(362-758) | 678 (464-940) | 25.0% | 10 (7-14) | 10 (7-14) | −3.9% |
| Forces of nature, war, and legal intervention | 1399 (903-2080) | 2289 (1550-3341) | 63.6% | 26 (17-39) | 33 (22-48) | 25.9% |
| Exposure to forces of nature | 173 (110-269) | 2187 (1480-3210) | 1164.7% | 3(2-5) | 32 (21-47) | 873.1% |
| Collective violence and legal intervention | 1226 (779-1854) | 102 (66-153) | −91.7% | 23 (15-35) | 1 (1-2) | −93.6% |
Data are YLDs (95% uncertainty interval) or percentage change (%A). G6PD=glucose-6-phosphate dehydrogenase deficiency. Ecoli=Escherichia coli. H influenzae=Haemophilus influenzae. S pneumoniae=Streptococcus pneumoniae.